Ramipril - Moligand™, 10mM in DMSO , Inhibitor of Angiotensin-converting enzyme, CAS No.87333-19-5, Inhibitor of Angiotensin-converting enzyme

CAS: 87333-19-5 Cat. No.: R409196 Formula: C₂₃H₃₂N₂O₅ Peso molecolare: 416.51 Numero EC: 642-904-3 PubChem CID: 5362129

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

(2S,​3aS,​6aS)​-1-​[(2S)​-​2-​[[(1S)​-​1-​(ethoxycarbonyl)​-​3-​phenylpropyl]​amino]​-​1-​oxopropyl]​octahydro-cyclopenta[b]​pyrrole-​2-​carboxylic acid

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Panoramica

Information

Ramipril is anangiotensin-converting enzyme (ACE)inhibitor withIC50of 5 nM.
In vitro

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM. Ramipril enhances the activity of ACE-associated CK2 and the phosphorylation of ACE Ser¹²⁷⁰ in cultured endothelial cells, but is unable to activate JNK or stimulate the nuclear accumulation of c-Jun in endothelial cells expressing a S1270A ACE mutant or in ACE-deficient cells. Prolonged Ramipril treatment increases ACE expression in primary cultures of human endothelial cells and in vivo (mouse lung), which can be prevented by pretreatment with the JNK inhibitor SP600125. Ramipril displays little enhanced effect on the rate of in vitro endothelial apoptosis induced by the serum deprivation method.

In vivo

Chronic in vivo administration of Ramipril to rats at a dosage that has similar hypotensive effects in vitro HUVECs significantly reduces the rate of LPS-induced apoptosis compared to the other ACE inhibitors, which contrasts with the apoptosis effect in vitro. Ramipril inhibits systolic blood pressure (SBP) with IC50 of 1.97 mg/kg in spontaneously hypertensive rats (SHR). When in combination with AT1-receptor blockade by candesartan-cilexetil increases SBP reduction synergistically rather than additively. Administration of Ramipril to spontaneously hypertensive rats (SHR) produces significant inhibition of aorta ACE and lung ACE with IC50 ~5 mg/kg, but shows little effect for brain ACE ex vivo. Ramipril prevents beta cell dysfunction in osteoprotegerin treated mice through decreasing islet monocyte/macrophage infiltration, fibrosis and apoptosis involving decreasing RAS, growth factor genes and inflammatory molecules expressions.
Cell Data

cell lines：

Concentrations：~1 μM

Incubation Time：24 hours

Powder Purity:≥99%

Specifications

Sinonimi

(2S,​3aS,​6aS)​-1-​[(2S)​-​2-​[[(1S)​-​1-​(ethoxycarbonyl)​-​3-​phenylpropyl]​amino]​-​1-​oxopropyl]​octahydro-cyclopenta[b]​pyrrole-​2-​carboxylic acid

Specifiche e purezza

Moligand™, 10mM in DMSO

Meccanismi biochimici e fisiologici

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.

Condizioni di conservazione di stoccaggio

Store at -80°C

Spedito in

Dry ice packs + Cold packs

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Grado

Moligand™

Tipo di azione

INHIBITOR

Meccanismo d'azione

Inhibitor of Angiotensin-converting enzyme

Proprietà del prodotto

• ALogP: 1.4

Nomi e identificatori

• Isomeri SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
• WGK Germania: 2
• RTECS: GY5879600
• CAS alternativo: 87333-19-5
• PubChem CID: 5362129
• Numero NSC: 758933
• Termini MeSH: Acovil;Altace;Carasel;Delix;HOE 498;HOE-498;HOE498;Ramace;Ramipril;Triatec;Tritace;Vesdil;Zabien
• Peso molecolare: 416.51

Obiettivi associati (umani)

ACE Tclin Angiotensin-converting enzyme (2 Activities)

Discover Target: ACE

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Proprietà chimiche e fisiche

• Solubilità: Solubility (25°C) In vitro DMSO: 30 mg/mL (197.17 mM); Ethanol: -1 mg/mL
• Rotazione specifica [α]: 40° (C=1,0.1 NHCl in EtOH)
• Punto di fusione (°C): 109 °C

Riferimenti

1. Kai Liu, Xing Zhao, Xue Qi, Dong-Liang Hou, Hao-Bin Li, Yu-Hao Gu, Qing-Long Xu.  (2021)  Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.  EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,      [PMID:33784603] [10.1016/j.ejmech.2021.113388]